A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

Recruiting

Phase 3

Amivantamab & PembrolizumabA Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

Sponsor:

Janssen Research & Development, LLC

Code:

NCT07276399

Conditions

Squamous Cell Carcinoma of Head and Neck

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Amivantamab

Pembrolizumab

Carboplatin

5-Flurouracil

Cisplatin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-25. This information was provided to ClinicalTrials.gov by Janssen Research & Development, LLC on 2025-12-19.